Table 1 Survival prediction in human patients using model-specific metabolites
From: Metabolomics of oncogene-specific metabolic reprogramming during breast cancer
Value for met signature (no. of metabolites in signature) | P value (10) | P value (9) | P value (8) | P value (7) | Metabolites used in COX proportional hazard model |
|---|---|---|---|---|---|
Normal | 0.002 | 0.001 | 0.003 | 0.01 | Citrate; nicotinamide adenine dinucleotide (NAD+); gamma-glutamyltyrosine; S-adenosylhomocysteine (SAH); glycerophosphorylcholine (GPC); gamma-glutamylglutamate; choline phosphate; ribose; mannitol$; Isobar: ribulose 5-phosphate#, xylulose 5-phosphate* |
Wnt1 | 0.79 | 0.786 | 0.72 | 0.63 | 2-Linoleoylglycerophosphoethanolamine; glycylleucine; margarate (17:0); creatine; 10-nonadecenoate (19:1n9); threonate; cytidine 5′-diphosphocholine; eicosenoate (20:1n9 or 11)$; lysine#; 2-hydroxyglutarate* |
Neu | 0.82 | 0.746 | 0.65 | 0.55 | 2-Linoleoylglycerophosphoethanolamine; N-acetylaspartate (NAA); pipecolate; glycerol 3-phosphate (G3P); dihomo-linoleate (20:2n6); dihomo-linolenate (20:3n3 or n6); stearoyl sphingomyelin; N6-acetyllysine$; trans-4-hydroxyproline#; docosapentaenoate (n3 DPA; 22:5n3)* |
C3-TAg | 0.009 | 0.03 | 0.02 | 0.02 | Gamma-glutamyltyrosine; choline phosphate; Isobar: ribulose 5-phosphate, xylulose 5-phosphate; ribitol; gamma-glutamylalanine; thymine; maltotriose; ribulose$; choline#; 5-oxoproline* |
PyMT | 0.05 | 0.04 | 0.07 | 0.04 | Gamma-glutamyltyrosine; S-adenosylhomocysteine (SAH); choline phosphate; stearoylcarnitine; phenyllactate (PLA); Isobar: ribulose 5-phosphate, xylulose 5-phosphate; cystine; N-acetylaspartate (NAA)$; gamma-glutamylalanine#; 2-hydroxyglutarate* |
PyMT-DB | 0.61 | 0.57 | 0.48 | 0.37 | Ribose; maltose; margarate (17:0); 10-nonadecenoate (19:1n9); maltotriose; cytidine 5′-diphosphocholine; urea; glutathione, oxidized (GSSG)$; oleate (18:1n9)#; 10-heptadecenoate (17:1n7)* |